Investor Presentaiton slide image

Investor Presentaiton

55 Investor presentation Full year 2022 Novo NordiskⓇ ONWARDS 4 achieved primary endpoint of HbA 1c non-inferiority with no statistically significant difference in hypoglycaemic events Change in HbA1c from baseline over time 26 weeks Time since randomisation (weeks) Overall hypoglycaemic episodes in the trial Change from baseline (%) 0.0 -0.4 -0.8 -1.2 10 HH 18 КН 26 26* On treatment Insulin icodec Insulin glargine U100 N (%) E R N (%) E R Level 2: Clinically 148 (50.9) 937 5.60 160 (55.0) 935 5.61 significant hypo Level 3: (1.4) 7 0.04 (0.7) 3 0.018 -1.16% Severe hypo Level 3 or 2: -1.18% Severe or clinically 150 (51.5) 944 5.64 162 (55.7) 938 5.62 significant hypo -1.6 Once-weekly insulin icodec Once-daily insulin glargine U100 Note: Overall baseline HbA1c of 8.3% * Lines are based on observed data where the value denoted after 26 weeks is estimated mean value derived based on multiple imputation Hypo: hypoglycaemia; N: Number of subjects with one or more events, %: Percentage of subjects with one or more events; E: Number of events; R: Rate (number of events per patient year of exposure, hypoglycaemia alert value (level 1): Plasma glucose value of <3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by blood glycose meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
View entire presentation